We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is The Ensign Group (ENSG) Stock Outpacing Its Medical Peers This Year?
Read MoreHide Full Article
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is Ensign Group (ENSG - Free Report) one of those stocks right now? Let's take a closer look at the stock's year-to-date performance to find out.
Ensign Group is one of 997 companies in the Medical group. The Medical group currently sits at #7 within the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Ensign Group is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for ENSG's full-year earnings has moved 0.2% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
According to our latest data, ENSG has moved about 14.5% on a year-to-date basis. Meanwhile, the Medical sector has returned an average of -5.1% on a year-to-date basis. This means that Ensign Group is outperforming the sector as a whole this year.
Boston Scientific (BSX - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 14.6%.
For Boston Scientific, the consensus EPS estimate for the current year has increased 2.3% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Ensign Group belongs to the Medical - Nursing Homes industry, which includes 2 individual stocks and currently sits at #96 in the Zacks Industry Rank. Stocks in this group have gained about 17.1% so far this year, so ENSG is slightly underperforming its industry this group in terms of year-to-date returns.
In contrast, Boston Scientific falls under the Medical - Products industry. Currently, this industry has 83 stocks and is ranked #159. Since the beginning of the year, the industry has moved +4.6%.
Investors interested in the Medical sector may want to keep a close eye on Ensign Group and Boston Scientific as they attempt to continue their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is The Ensign Group (ENSG) Stock Outpacing Its Medical Peers This Year?
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is Ensign Group (ENSG - Free Report) one of those stocks right now? Let's take a closer look at the stock's year-to-date performance to find out.
Ensign Group is one of 997 companies in the Medical group. The Medical group currently sits at #7 within the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Ensign Group is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for ENSG's full-year earnings has moved 0.2% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
According to our latest data, ENSG has moved about 14.5% on a year-to-date basis. Meanwhile, the Medical sector has returned an average of -5.1% on a year-to-date basis. This means that Ensign Group is outperforming the sector as a whole this year.
Boston Scientific (BSX - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 14.6%.
For Boston Scientific, the consensus EPS estimate for the current year has increased 2.3% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Ensign Group belongs to the Medical - Nursing Homes industry, which includes 2 individual stocks and currently sits at #96 in the Zacks Industry Rank. Stocks in this group have gained about 17.1% so far this year, so ENSG is slightly underperforming its industry this group in terms of year-to-date returns.
In contrast, Boston Scientific falls under the Medical - Products industry. Currently, this industry has 83 stocks and is ranked #159. Since the beginning of the year, the industry has moved +4.6%.
Investors interested in the Medical sector may want to keep a close eye on Ensign Group and Boston Scientific as they attempt to continue their solid performance.